ClinicalTrials.gg
CompletedNCT03340753Updated Dec 16, 2025

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

A Phase 1 interventional study of KBP-5074 Capsule and KBP-5074 Tablet in Bioequivalence, sponsored by KBP Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by KBP Biosciences · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is an open-label, partial crossover, single-dose study to evaluate the pharmacokinetics (PK), dose proportionality, and safety/tolerability of tablet versus capsule formulations of KBP-5074 in healthy subjects. The study is designed to evaluate the PK of a new tablet formulation versus that of the current capsule formulation. Data derived from this study, in addition to preclinical data and chemistry, manufacturing, and controls, will provide a basis for dose selection in future studies.

Read the detailed description

Twenty healthy subjects will be allocated 4:1 to either the crossover study groups (16 subjects) or to the 0.25 mg tablet single dose treatment (4 subjects). Subjects allocated to the crossover study groups will be randomized 1:1 to 0.5 mg tablet/capsule (8 subjects) or 1.0 mg tablet/capsule (8 subjects).

Within the crossover study groups, subjects will be further randomized to receive a single dose of KBP-5074 (0.5 mg or 1.0 mg) in either capsule or tablet formulation in a 2-period crossover design with a 2-week washout period. The study duration for subjects in the crossover study groups will be approximately 7 weeks, which includes a 3-week screening period, and the 2 crossover single dose periods, which will be followed by a 2-week washout/follow-up period, respectively.

Subjects allocated to the 0.25 mg dose cohort (n=4) will receive a single dose of 0.25 mg in tablet formulation only. The 0.25 mg tablet cohort will provide additional data for the evaluation of dose exposure for the tablet formulation. The study duration for the single dose arm will be 5 weeks, which includes a 3-week screening period, and the single dose which will be followed by a 2 week washout period.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

KBP Biosciences is the lead sponsor of 12 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physically and mentally healthy male and females, aged 18 to 45, inclusive;
  • (BMI) between 18 to 30 kg/m2, inclusive;
  • Nicotine-free (cigarettes, pipe, cigar, chewing tobacco, nicotine patches, etc.) for at least 6 months prior to Screening until the end of the study;
  • Normal renal function as defined by estimated >90 mL/min/1.73m2;
  • Willing to remain in the study facility for the duration of the domicile period and able to return for all out-patient visits;
  • Ability to understand and sign written , which must be obtained prior to any study-related procedures being completed;
  • Willing to avoid adding salt substitutes that contain potassium chloride or potassium lactate to food from 7 days prior to dosing through the duration of the study;
  • Women of (WOCBP), must agree to 2 medically accepted, effective methods of during the study and for 90 days after the end of the study. Adequate methods of contraception are defined as those that result in a low failure rate (\<1% per year) when used consistently and correctly. Such methods include the use of oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products (such as an intrauterine diaphragm, condoms, or spermicides);
  • Women of childbearing potential are defined as women who are not surgically or chemically sterilized, including hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable), and who are between menarche and 1 year ; and
  • Post-menopausal is defined as amenorrhoeic for at least 1 year prior to screening AND, if aged under 45 years have a serum follicle stimulating hormone (FSH) level of at least 30 IU/L. Women who are taking hormone replacement therapy (HRT) do not have to have FSH assessments, but the amenorrhea (before starting HRT) must have been naturally (spontaneously) occurring and have been accompanied by an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms);
  • Males with partners who are WOCBP must agree to use condoms plus spermicide and their female partner must also be using contraception (e.g., hormonal or intra-uterine device). This double contraception must be used from the first dose of study drug until at least 90 days after the last dose of study drug;
  • Males must also refrain from donating sperm during the study and for 90 days after the last dose;
  • Negative urine test for drugs of abuse (opiates, benzodiazepines, amphetamines, cannabinoids including tetrahydrocannabinol, cocaine, barbiturates, and phencyclidine), nicotine/cotinine, and breath alcohol test at Screening and Check-in; and
  • Is in good general health as determined by the Investigator's review of medical history, concomitant medications, physical examination, and clinical laboratory and (ECG) evaluations at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any illness, that, in the opinion of the Investigator, could confound the results of the study or pose an additional risk to the subject by their participation in the study ;
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease;
  • Any surgical or medical condition that could interfere with the absorption, distribution, metabolism, or excretion of the IMP;
  • History of any drug allergy as per the Investigator's judgment;
  • History of alcohol abuse or illicit drug use within 2 years of Screening;
  • Use of marijuana (including prescribed marijuana) within 3 months prior to Screening;
  • Use of nicotine within 6 months prior to screening;
  • Use of any prescription or over-the-counter medication, vitamins/herbal supplements (with the exception of hormonal or HRT and sporadic use of acetaminophen or ibuprofen) within 7 days (14 days if the drug is a potential enzyme inducer) prior to study allocation;
  • Has taken any medicinal product (IMP) within 30 days or 5 half-lives of that IMP (whichever is longer) prior to dosing;
  • Donation of blood or blood products within 30 days of dosing;
  • Acute illness within 14 days of dosing; acute illness occurring prior to the 14 days before dosing must show signs of complete recovery;
  • Regular caffeine consumption of >300 mg/day (i.e., approximately 3 cups [8 fluid ounces] of coffee or 10 cans [12 fluid ounces] of cola) 7 days prior to dosing. Inability to restrict consumption of caffeine during the domicile period;
  • Positive serologic findings for (HIV), virus (HBV) or virus (HCV);
  • Diets that could alter metabolism (i.e., vegetarian, high protein, Slim Fast®, Nutrisystem®, etc.) 7 days prior to dosing;
  • Weight loss or gain of ≥10% in the 30 days prior to dosing;
  • Strenuous exercise (>5 per week) within 2 weeks prior to dosing;
  • Positive urinary cotinine level, breath alcohol, or drug screen at Screening and/or admission (both admissions for subjects in the crossover treatment group);
  • Systolic BP >140 mmHg or \<90 mmHg or diastolic BP >90 mmHg or \<60 mmHg at Screening with 1 repeat allowed per Investigator discretion at Screening and Day -1 (and Day 14 for subjects in the crossover treatment group period 2);
  • Heart rate \<40 bpm or >100 bpm at Screening;
  • Consumption of any nutrients known to modulate cytochrome P450 3A4 () or any strong inhibitors or inducers of CYP3A4, starting from 14 days prior to the first dose of study drug at Day 1 until the end of study assessments. Inability to refrain from consumption of grapefruit and Seville oranges or St. John's wort (14 days prior to dosing and during the study);
  • Positive pregnancy test result;
  • Subject has any finding that, in the view of the Investigator and/or Medical Monitor, would compromise the subject's safety; or
  • The Investigator has any reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    KBP-5074 Capsule

    KBP-5074 capsule, 0.5 mg or 1.0 mg, QD, single dose

    Drug: KBP-5074 Capsule

  • Experimental
    KBP-5074 Tablet

    KBP-5074 tablet, 0.5 mg or 1.0 mg, QD, single dose

    Drug: KBP-5074 Tablet

Interventions

  • DrugKBP-5074Studies of KBP-5074KBP-5074 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period

    Also known as: MRA

  • DrugKBP-5074Studies of KBP-5074KBP-5074 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period

    Also known as: MRA

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable plasma concentration

    Time frame: Through 312 hours

07

Study locations

1 site
  • Medpace CLinical Pharmacology
    Cincinnati, Ohio 45227, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2017
First posted
Nov 13, 2017
StartActual
Oct 26, 2017
Primary completionActual
Nov 22, 2017
CompletionActual
Dec 19, 2017
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03340753
Lead sponsor
KBP Biosciences
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Oct 26, 2017
Primary completion
Nov 22, 2017
Completion
Dec 19, 2017
Last update
Dec 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KBP-5074

Start the discussion